Navigation Links
TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
Date:12/5/2011

MALVERN, Pa., Dec. 5, 2011 /PRNewswire/ -- TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule Smac mimetic drugs to treat cancer, today announced the initiation of a Phase 1/2 clinical trial of its lead Smac mimetic drug candidate, TL32711, in elderly patients with acute myelogenous leukemia (AML). The investigator-initiated study is being conducted at the Hospital of the University of Pennsylvania and is an open-label, non-randomized trial that will evaluate the safety, tolerability and clinical response activity of TL32711 in patients aged 60 years or greater who have relapsed or primary refractory AML.

"In preclinical studies on primary human AML samples, TL32711 inhibits the growth and survival of AML cells as demonstrated in colony forming assays and a xenotransplantation model of the disease," said Martin Carroll, M.D., of the Hospital of the University of Pennsylvania. "These encouraging data along with TL32711's novel mechanism of action support its clinical development for AML where new treatment options are needed especially for the elderly."

"This clinical study represents another important step in advancing TL32711 as a potential treatment for AML and supports our goal of providing improved therapies for patients with cancer," said John Gill, TetraLogic's President and Chief Executive Officer.  "The ability of TL32711 to antagonize Inhibitor of Apoptosis Proteins (IAPs) represents a new broadly applicable approach to treat cancers that are normally resistant to therapies, including AML."

About TL32711
TL32711 is a small molecule peptidomimetic of Smac (Second mitochondrial-derived activator of caspases) an endogenous regulator of apoptotic cell death that selectively antagonizes multiple IAPs. TL32711 has demonstrated preclinical anti-tumor activity that supports its clinical development for solid tumor and hematological mali
'/>"/>

SOURCE TetraLogic Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
3. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
4. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
5. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
6. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
7. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
8. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
9. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
10. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
11. Lotus Pharmaceuticals Announces Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... Global HIV Infection Drug Market and Pipeline ... The rate of HIV infection and the number of deaths ... a positive rate across the globe. It has been estimated ... to 1.5 in 2013, with the rates for children being ... in the infection rates has been the improved access to ...
(Date:8/18/2014)... DALLAS , August 18, 2014 ... "Membrane Bioreactor Systems Market, By Application (Municipal Wastewater ... Fiber, Flat Sheet and Multi Tubular), By Configuration ... to 2019", published by MarketsandMarkets, The market for ... million by 2019, growing at a CAGR of ...
(Date:8/18/2014)... 2014 Dyadic International, Inc. ("Dyadic") (OTCQX: ... proprietary technologies are used to develop, manufacture and ... bio-based chemical, biopharmaceutical and industrial enzyme industries, announced ... on Form 10 with the U.S. Securities and ... http://photos.prnewswire.com/prnh/20110621/CL06708LOGO The Form ...
(Date:8/18/2014)... , 18. August 2014 Vier ... eine internationale klinische Studie auf, in der ... Linse soll das Sehvermögen bei allen Entfernungen ... Operation möglicherweise keine Lese- oder Gleitsichtbrille mehr ... Namen FluidVision Accommodating Intraocular Lens ...
Breaking Biology Technology:Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 2Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 3Dyadic International Files Form 10 Registration Statement 2Dyadic International Files Form 10 Registration Statement 3Dyadic International Files Form 10 Registration Statement 4Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 2Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 3Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 4
... Columbus Children's Hospital announced on Tuesday that ... Ltd. to purchase the information system CardioIMS. The system ... Center , which addresses the needs of children and ... based on an in-depth study of the Center's administrative ...
... has announced that the southwestern laboratory network TriCore ... Virus genotyping reagents. , ,The reagents are part of tests ... virus, a blood-transmitted disease estimated to be chronic in 4 ... do not know it, according to Third Wave's company statement. ...
... Wingra Technologies announced on Thursday the release ... product, helps move mail, personal address books, calendars and ... Exchange format. , ,The software can handle multiple users' ... , ,"We've learned first-hand how complex and tedious a ...
Cached Biology Technology:Children's Hospital chooses Camtronics for cardiology IT system 2
(Date:8/19/2014)... . Taking ... activity in children,Today the Canadian Society of Exercise Physiology ... activity and published their position and recommendations in the ... APNM ). This position stand provides an important ... physical activity for children and suggests both practical guidelines ...
(Date:8/19/2014)... Although body motion sensors already exist in different forms, ... complexity and cost of production. Now researchers from the ... the first time treated common elastic bands with graphene, ... for medical use and can be made cheaply. ... By fusing this material with graphene - which imparts ...
(Date:8/19/2014)... that protect their young have bigger brains than counterparts ... of British Columbia study. , Stickleback fish are well ... the male of the species, rather than the female, ... than females and researchers wanted to find out if ... as caregivers. , In the study, published recently ...
Breaking Biology News(10 mins):Taking a stand: Balancing the BENEFITS and RISKS of physical activity in children 2Taking a stand: Balancing the BENEFITS and RISKS of physical activity in children 3
... of Veterinary Bacteriology, University of Bern, Switzerland, has ... (ASM) to receive a 2011 ICAAC Young Investigator ... and molecular biology to investigate the impact of ... caused by Gram-negative bacteria. Sponsored by the ASM, ...
... New research by University of New Hampshire exercise ... effective tool for gauging exercise intensity, but that it ... other more objective tests. In a study published recently ... of kinesiology Timothy Quinn and his former graduate student ...
... CORONA, Calif., Sept. 13, 2011 AVT, Inc., ... ), continues to revolutionize the vending and automated ... provides prescription medicine refills directly to consumers, 24-hours ... or store employee. This breakthrough system ...
Cached Biology News:The American Society for Microbiology honors Andrea Endimiani 2The American Society for Microbiology honors Andrea Endimiani 3New UNH data tests the exercise 'talk test' 2
... Sequencing Quality 96 Well ... BAC template preparation from 1.5ml ... suitable for automated fluorescent sequencing ... DNA; Utilizes ProPrep strategy which ...
...
TLN2 Antibody...
Olig2 Immunogen: Synthetic peptide from rat. Available Date: 9-19-2006...
Biology Products: